23 May 2013
Keywords: negative, press, compromised, vytorin, first-line, therapy, dr
Article | 17 November 2008
Merck & Co/Schering-Plough\'s promotion of Vytorin (ezetimibe and simvastatin) as a first-line agent in the treatment of dyslipidemia has
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
17 November 2008
1 December 2008
3 November 2008
© 2013 thepharmaletter.com